secwatch.observer — SEC 8-K summary
======================================

Issuer:     Xencor Inc (XNCR)
CIK:        0001326732
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001326732-25-000086
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Xencor narrows Q3 net loss to $6M; advances key bispecific antibodies toward pivotal studies
--------------------------------------------------------------------------------

- Net loss $6.0M ($0.08 per share) vs $46.3M loss ($0.72) in Q3 2024; revenue $21.0M, up from $17.8M.
- Cash $633.9M at Sept 30, 2025; expects year-end cash $570-590M and runway into 2028.
- XmAb819 (ccRCC) and XmAb541 (gynecologic/germ cell) show early PRs; Phase 3 dose selection in 2026; pivotal studies targeted for 2027.
- First patient dosed in plamotamab Phase 1b RA study; XmAb942 Phase 2b XENITH-UC enrolling; XmAb657 and XmAb412 studies on track.
- Partners advancing: Amgen Phase 3 XALience for xaluritamig; Astellas data on ASP2138; Zenas positive Phase 2 in MS.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000086/0001326732-25-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326732/000132673225000086/xncr-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001326732-25-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer